title: Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
abstract: Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials. However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence. Here, we present the novel first-generation "type II" FLT3 inhibitors, AFG206, AFG210, and AHL196, and the second-generation "type II" derivatives and AST487 analogs, AUZ454 and ATH686. All agents potently and selectively target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. Cross-resistance between "type I" inhibitors, PKC412 and AAE871, was demonstrated. While cross-resistance was also observed between "type I" and first-generation "type II" FLT3 inhibitors, the high potency of the second-generation "type II" inhibitors was sufficient to potently kill "type I" inhibitor-resistant mutant FLT3-expressing cells. The increased potency observed for the second-generation "type II" inhibitors was observed to be due to an improved interaction with the ATP pocket of FLT3, specifically associated with introduction of a piperazine moiety and placement of an amino group in position 2 of the pyrimidine ring. Thus, we present 2 structurally novel classes of FLT3 inhibitors characterized by high selectivity and potency toward mutant FLT3 as a molecular target. In addition, presentation of the antileukemic effects of "type II" inhibitors, such as AUZ454 and ATH686, highlights a new class of highly potent FLT3 inhibitors able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot.
authors.affiliation: Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: Ellen
authors.initials: E
authors.lastname: Weisberg
authors.forename: Johannes
authors.initials: J
authors.lastname: Roesel
authors.forename: Pascal
authors.initials: P
authors.lastname: Furet
authors.forename: Guido
authors.initials: G
authors.lastname: Bold
authors.forename: Patricia
authors.initials: P
authors.lastname: Imbach
authors.forename: Andreas
authors.initials: A
authors.lastname: Flörsheimer
authors.forename: Georgio
authors.initials: G
authors.lastname: Caravatti
authors.forename: Jingrui
authors.initials: J
authors.lastname: Jiang
authors.forename: Paul
authors.initials: P
authors.lastname: Manley
authors.forename: Arghya
authors.initials: A
authors.lastname: Ray
authors.forename: James D
authors.initials: JD
authors.lastname: Griffin